X 
Board Meetings
Home | Market Info | Company Profile | Board Meetings
Aptus Pharma Ltd.
BSE CODE: 544529   |   NSE CODE: NA   |   ISIN CODE : INE15XJ01010   |   24-Jun-2026 Hrs IST
BSE NSE
Rs. 233.45
4.55 ( 1.99% )
 
Prev Close ( Rs.)
228.90
Open ( Rs.)
233.45
 
High ( Rs.)
233.45
Low ( Rs.)
233.30
 
Volume
12000
Week Avg.Volume
NA
 
52 WK High-Low Range(Rs.)
BSE NSE
Rs.
( )
 
Prev Close ( Rs.)
Open ( Rs.)
 
High ( Rs.)
Low ( Rs.)
 
Volume
Week Avg.Volume
NA
 
52 WK High-Low Range(Rs.)
Source DateBoard Meeting DateDetails
09-Jun-2026 12-Jun-2026 Preferential Issue of shares Inter alia, to consider and deliberate upon the following proposed agenda item:- I. To consider, evaluate and deliberate upon the proposal for raising of funds through: (a) issuance of equity shares and / or any other eligible securiOes by way of PreferenOal Allotment, in accordance with the provisions of the SecuriOes and Exchange Board of India (Issue of Capital and Disclosure Requirements) RegulaOons, 2018, as amended ("SEBI ICDR RegulaOons"), the Companies Act, 2013 and rules framed thereunder, and other applicable laws and regulaOons, subject to such approvals, permissions and sancOons of the shareholders of the Company and / or regulatory and statutory authoriOes as may be required; and (b) Borrowings from banks / financial insOtuOons / other lenders. II. To consider and, if thought fit, to authorize the Managing Director of the Company to (a) idenOfy, evaluate and interact with prospecOve investor(s) / proposed allo?ee(s) in connecOon with the aforesaid proposed preferenOal allotment, and to finalize and place before the Board of Directors, at a subsequent meeOng, the list of proposed allottee(s) along with all requisite details as prescribed under the SEBI ICDR Regulations and the Companies Act, 2013, for consideraOon and approval of the Board. (b) idenOfy and approach prospecOve lenders for the borrowing requirements at the best available terms ? and to report back to the Board.
20-Apr-2026 27-Apr-2026 Audited Results
17-Mar-2026 24-Mar-2026 Bonus issue & Increase in Authorised Capital Inter alia, to consider a proposal for:- 1. Increase in Authorized Share Capital subject to approval of members of the Company. 2. Consideration and recommendation of Bonus Equity Shares subject to approval of Members of the Company.
03-Nov-2025 10-Nov-2025 Half Yearly Results
Page 1 of 1
PREV || NEXT